Register or Sign in to Save this opportunity, or Send an Inquiry.
HY209_SHAPERON Inc
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Sodium taurodeoxycholate for the treatment of sepsis
Send an Inquiry
RE:
Participants
You

Anti-inflammation (GPCR131 agonist): Based on the novel theory we suggested in 2004 on Nature Reviews Immunology, we identified a novel compound (HY209) that can ameliorate inflammatory diseases such as sepsis, collagen-induced arthritis and atopic dermatitis. It activates GPCR131 pathway inducing Myeloid-derived suppressor cells and regulatory B cells that can suppress inflammatory responses. Because HY209 increases myeloid-derived suppressor cells and regulatory B cells in vivo, the indication might be expanded to various inflammatory diseases like Alzheimer’s disease.

Type of Business Relationship Sought
<p>investment, research collaboration or technology licensing.</p>
FEATURED
Last Updated Feb 2018
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE

Opportunity Contact


Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833